Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 11/20 | 0.61 |
| ▸ | ADORA2B | P29275 | 10/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4759681 | 0.83 | ADORA2A (0.61) | ADORA2AADORA2BADORA3 | |
| SCHEMBL4758246 | 0.82 | ADORA2A (0.61) | ADORA2AADORA2BADORA3 | |
| SCHEMBL278299 | 0.82 | RNASEL (0.49) | ADORA2AADORA2BADORA3 | |
| SCHEMBL13403857 | 0.82 | RNASEL (0.49) | ADORA2AADORA2BADORA3 | |
| SCHEMBL4759356 | 0.81 | ADORA2A (0.65) | ADORA2AADORA2BADORA3 | |
| SCHEMBL14252600 | 0.81 | ADORA2A (0.58) | ADORA2AADORA2BADORA3 | |
| SCHEMBL278666 | 0.81 | ADORA3 (0.51) | ADORA2AADORA2BADORA3 | |
| SCHEMBL13403858 | 0.81 | ADORA3 (0.51) | ADORA2AADORA2BADORA3 | |
| SCHEMBL4757814 | 0.81 | ADORA3 (0.56) | ADORA2AADORA2BADORA3 | |
| SCHEMBL6762689 | 0.78 | ADORA1 (0.50) | ADORA2AADORA2BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342003-B2 | Synthesis of 2-aralkyloxyadenosines, 2-alkoxyadenosines, and their analogs | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2008-03-11 | — | — | US | disclosed |
| US-7342003-B2 | Synthesis of 2-aralkyloxyadenosines, 2-alkoxyadenosines, and their analogs | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2008-03-11 | — | — | US | disclosed |
| US-20060135466-A1 | Synthesis of 2-aralkyloxyadenosines, 2-alkoxyadenosines, and their analogs | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. | 2006-06-22 | — | — | US | disclosed |
| WO-2005033121-A2 | SYNTHESIS OF 2-ARALKYLOXYADENOSINES, 2-ALKOXYADENOSINES, AND THEIR ANALOGS | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135466-A1 | Synthesis of 2-aralkyloxyadenosines, 2-alkoxyadenosines, and their analogs | ADA, ADAR, DCTD | ADORA2A 7/4885ADORA2B 62/4885ADORA3 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.